Cubist Changes Internet Press Release Policy After FDA Letter On Daptomycin
Executive Summary
Cubist Pharmaceuticals will purge press releases from its website after six months in response to a Nov. 22 letter from FDA maintaining that Cubist's press releases available on the Internet amount to pre-approval promotion of Cidecin (daptomycin).
You may also be interested in...
Cubist Cubicin Ads Draw FDA Warning Letter For Broad Indication Claims
Cubist Cubicin journal ads and website claims for treatment of all infections caused by Staphylococcus aureus pose a "significant public health risk," an FDA warning letter to the company says
Cubist Cubicin Ads Draw FDA Warning Letter For Broad Indication Claims
Cubist Cubicin journal ads and website claims for treatment of all infections caused by Staphylococcus aureus pose a "significant public health risk," an FDA warning letter to the company says
Zyvox, Synercid Launches Indicate Market Receptivity To New Antibiotics
Pharmacia's Zyvox (linezolid) sales of $19 mil. in the two-and-a-half months from its U.S. commercial launch in mid-April until the end of the June 30 quarter put the product $4 mil. ahead of sales of the Aventis antibiotic Synercid (quinipristin/dalfopristin) in the second quarter of 2000.